An introduction to medicinal cannabis.
Hazekamp A. Volendam: Zwarthoed, 2013.
Chemical constituents of marijuana: the complex mixture of natural cannabinoids.
Elsohly MA, Slade D. Life Sci 2005; 78(5):539-48.
Chemistry and analysis of phytocannabinoids and other cannabis constituents.
Brenneisen R. En: ElSohly MA, ed. Marijuana and the cannabinoids. Totowa, New Jersey: Humana Press Inc, 2007. p.17-49.
Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material.
De Backer B, Debrus B, Lebrun P, Theunis L, Dubois N, Decock L, et al. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877(32):4115-24
Decreto N潞 46/015 (4 feb.2015).
Uruguay. Poder Ejecutivo.
Identification and quantification of cannabinoids in Cannabis sativa L. plants by high performance liquid chromatography-mass spectrometry.
Aizpurua-Olaizola O, Omar J, Navarro P, Olivares M, Etxebarria N, Usobiaga A. Anal Bioanal Chem 2014; 406(29):7549-60.
The inheritance of chemical phenotype in Cannabis sativa L.
de Meijer EP, Bagatta M, Carboni A, Crucitti P, Moliterni VM, Ranalli P, Mandolino G. Genetics 2003; 163(1):335-46.
Ley No 19.172 (20 dic. 2013).
Uruguay. Poder Legislativo.
Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications.
Galal AM, Slade D, Gul W, El-Alfy AT, Ferreira D, Elsohly MA. Recent Pat CNS Drug Discov 2009; 4(2):112-36.
Polyketide synthase activities and biosynthesis of cannabinoids and flavonoids in Cannabis sativa L. plants. En: Flores Sanchez IJ. Polyketide synthases in Cannabis sativa L.
Flores Sanchez IJ, Verpoorte R. Leiden: University Leiden, 2008. Cap.3, p.43-72.
Self-medication with cannabis. En: Pertwee RG, ed. Handbook of cannabis.
Hazekamp A, Pappas G. Oxford: Oxford University, 2014. Cap.17, p.319-37.
Sequence heterogeneity of cannabidiolic- and tetrahydrocannabinolic acid-synthase in Cannabis sativa L. and its relationship with chemical phenotype.
Onofri C, de Meijer EP, Mandolino G. Phytochemistry 2015; 116:57-68.
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo EB. Br J Pharmacol 2011; 163(7):1344-64.
That which we call Indica, by any other name would smell as sweet.
Erkelens JL, Hazekamp A. Cannabinoids 2014; 9(1):9-15.
The phytocannabinoid, ?9-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects.
Cascio MG, Zamberletti E, Marini P, Parolaro D, Pertwee RG. Br J Pharmacol 2015;172(5):1305-18.
Endocannabinoids and their pharmacological actions.
Pertwee RG. Handb Exp Pharmacol 2015; 231:1-37.
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, et al. Eur Neuropsychopharmacol 2015; 25(3):325-34.
Known pharmacological actions of nine nonpsychotropic phytocannabinoids. En: Pertwee RG, ed. Handbook of cannabis.
Cascio MG, Pertwee RG. Oxford:Oxford University, 2014. Cap.7, p.137-56.
Effectiveness of a marijuana expectancy manipulation: piloting the balanced-placebo design for marijuana.
Metrik J, Rohsenow DJ, Monti PM, McGeary J, Cook TA, de Wit H, et al. Exp Clin Psychopharmacol 2009; 17(4):217-25.
Known pharmacological actions of delta-9-tetrahydrocannabinol and of four other chemical constituents of cannabis that activate cannabinoid receptors.
Cascio MG, Pertwee RG. En: Pertwee RG, ed. Handbook of cannabis. Oxford: Oxford University, 2014. Cap.6, p.115-36.
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Neuropsychopharmacology 2010; 35(3):764-74.
Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol.
Huestis MA. Handb Exp Pharmacol 2005; 168:657-90.
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.
Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, et al. Clin Pharmacokinet 2015; 54(2):209-19.
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, et al. J Pharmacol Exp Ther 2010; 332(2):569-77.
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures.
Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, et al. Seizure 2012; 21(5):344-52.
Review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders.
Belendiuk KA, Baldini LL, Bonn-Miller MO. Addict Sci Clin Pract 2015; 10:10.
Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users.
Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Am J Drug Alcohol Abuse 2014; 40(1):23-30.
Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD.
Bonn-Miller MO, Babson KA, Vandrey R. Drug Alcohol Depend 2014; 136:162-5.
Cannabinoids in neurologic and mental disease.
Fattore L, ed. Cambridge, Massachusetts: Elsevier, 2015: 452 p.
Integrating cannabis into clinical cancer care.
Abrams DI. Curr Oncol 2016; 23(2):S8-S14.
Anticancer mechanisms of cannabinoids.
Velasco G,聽S谩nchez C,聽Guzm谩n M. Curr Oncol.聽2016;23(2):S23-32.
Canada鈥檚 Marihuana for Medical Purposes Regulations: a synopsis for health professionals.
Ziemianski D, Ware MA. J Hosp Adm. 2015; 4(5):79-83.
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.
Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. CMAJ 2010; 182(14):E694-701.
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).
Ware MA, Wang T, Shapiro S, Collet JP; COMPASS study team. J Pain. 2015; 16(12):1233-42.
Programming of neural cells by (endo) cannabinoids: from physiological rules to emerging therapies.
Maccarrone M, Guzm谩n M, Mackie K, Doherty P, Harkany T. Nat Rev Neurosci 2014; 15(12):786-801.
Towards the use of cannabinoids as antitumour agents.
Velasco G, S谩nchez C, Guzm谩n M. Nat Rev Cancer 2012; 12(6):436-44.
Endocannabinoid signaling in innate and adaptive immunity.
Chiurchiù V, Battistini L, Maccarrone M. Immunology. 2015 Jan 14. [Epub ahead of print]
Endocannabinoid signaling at the periphery: 50 years after THC.
Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, et al. Trends Pharmacol Sci. 2015 May;36(5):277-96.
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.
Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. Trends Pharmacol Sci. 2009 Aug;30(8):411-20.
